RWD suggests ADHD medication may be viable to treat genetic movement disorder

Researchers from the University of Maryland School of Medicine (MD, USA) have utilized anecdotal real-world evidence to investigate the viability of lisdexamfetamine as a treatment for KCNMA1-linked channelopathy. The findings have been published in Movement Disorders Clinical Practice. The genetic disorder, named after the gene affected, can lead to involuntary collapsing episodes. These incidents are noted to occur up to 300 times per day, which heightens the risk of serious injury. 75 individuals worldwide have been identified as having the disorder, with the first recorded case appearing in 2005. Real-world evidence highlighting progress towards treatment emerged in 2019, when a...